Do analysts rate ICCC or AKBA?

Akebia Therapeutics has a consensus price target of $4.67, suggesting a potential upside of 233.33%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akebia Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media favor ICCC or AKBA?

In the previous week, ImmuCell and ImmuCell both had 5 articles in the media. Akebia Therapeutics' average media sentiment score of 1.55 beat ImmuCell's score of 0.65 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer LRMR or ICCC?

Larimar Therapeutics currently has a consensus target price of $12.71, indicating a potential upside of 241.78%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Larimar Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.09 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer LRMR or ICCC?

In the previous week, Larimar Therapeutics had 3 more articles in the media than ImmuCell. MarketBeat recorded 8 mentions for Larimar Therapeutics and 5 mentions for ImmuCell. Larimar Therapeutics' average media sentiment score of 1.07 beat ImmuCell's score of 0.65 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmuCell 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ICCC or XFOR?

X4 Pharmaceuticals has a consensus price target of $9.70, suggesting a potential upside of 141.29%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 X4 Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Does the media favor ICCC or XFOR?

In the previous week, ImmuCell and ImmuCell both had 5 articles in the media. ImmuCell's average media sentiment score of 0.65 beat X4 Pharmaceuticals' score of 0.63 indicating that ImmuCell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer FHTX or ICCC?

Foghorn Therapeutics currently has a consensus price target of $11.43, suggesting a potential upside of 112.43%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Foghorn Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor FHTX or ICCC?

In the previous week, Foghorn Therapeutics and Foghorn Therapeutics both had 5 articles in the media. Foghorn Therapeutics' average media sentiment score of 0.66 beat ImmuCell's score of 0.65 indicating that Foghorn Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ImmuCell 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZSQR or ICCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

ImmuCell (ICCC) Competitors

$11.72 +0.64 (+5.78%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$11.76 +0.04 (+0.38%)

As of 07/14/2026 04:10 PM Eastern

Compare

ICCC vs. AKBA, LRMR, XFOR, FHTX, and ZSQR

Should you buy ImmuCell stock or one of its competitors? MarketBeat compares ImmuCell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImmuCell include Akebia Therapeutics (AKBA), Larimar Therapeutics (LRMR), X4 Pharmaceuticals (XFOR), Foghorn Therapeutics (FHTX), and Coeptis Therapeutics (ZSQR). These companies are all part of the "pharmaceutical products" industry.

How does ImmuCell compare to Akebia Therapeutics?

ImmuCell (NASDAQ:ICCC) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 5.7% of ImmuCell shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ImmuCell has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

ImmuCell has a net margin of -1.82% compared to Akebia Therapeutics' net margin of -8.83%. ImmuCell's return on equity of -1.88% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

In the previous week, ImmuCell and ImmuCell both had 5 articles in the media. Akebia Therapeutics' average media sentiment score of 1.55 beat ImmuCell's score of 0.65 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Akebia Therapeutics has a consensus price target of $4.67, suggesting a potential upside of 233.33%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akebia Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

ImmuCell has higher earnings, but lower revenue than Akebia Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.84	-$1.04M	-$0.06	N/A
Akebia Therapeutics	$236.20M	1.59	-$5.34M	-$0.08	N/A

Summary

ImmuCell beats Akebia Therapeutics on 8 of the 15 factors compared between the two stocks.

How does ImmuCell compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by company insiders. Comparatively, 5.7% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Larimar Therapeutics currently has a consensus target price of $12.71, indicating a potential upside of 241.78%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Larimar Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ImmuCell has higher revenue and earnings than Larimar Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
ImmuCell	$27.64M	3.84	-$1.04M	-$0.06	N/A

Larimar Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Larimar Therapeutics has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
ImmuCell	-1.82%	-1.88%	-1.22%

In the previous week, Larimar Therapeutics had 3 more articles in the media than ImmuCell. MarketBeat recorded 8 mentions for Larimar Therapeutics and 5 mentions for ImmuCell. Larimar Therapeutics' average media sentiment score of 1.07 beat ImmuCell's score of 0.65 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmuCell	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Larimar Therapeutics beats ImmuCell on 10 of the 16 factors compared between the two stocks.

How does ImmuCell compare to X4 Pharmaceuticals?

ImmuCell (NASDAQ:ICCC) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

X4 Pharmaceuticals has a consensus price target of $9.70, suggesting a potential upside of 141.29%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

ImmuCell has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

In the previous week, ImmuCell and ImmuCell both had 5 articles in the media. ImmuCell's average media sentiment score of 0.65 beat X4 Pharmaceuticals' score of 0.63 indicating that ImmuCell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmuCell has a net margin of -1.82% compared to X4 Pharmaceuticals' net margin of -1,106.30%. ImmuCell's return on equity of -1.88% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

ImmuCell has higher earnings, but lower revenue than X4 Pharmaceuticals. ImmuCell is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.84	-$1.04M	-$0.06	N/A
X4 Pharmaceuticals	$35.11M	10.80	-$79.20M	-$4.54	N/A

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 5.7% of ImmuCell shares are held by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ImmuCell beats X4 Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does ImmuCell compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

ImmuCell has lower revenue, but higher earnings than Foghorn Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	10.22	-$74.28M	-$1.16	N/A
ImmuCell	$27.64M	3.84	-$1.04M	-$0.06	N/A

ImmuCell has a net margin of -1.82% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
ImmuCell	-1.82%	-1.88%	-1.22%

Foghorn Therapeutics currently has a consensus price target of $11.43, suggesting a potential upside of 112.43%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Foghorn Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Foghorn Therapeutics has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 5.7% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Foghorn Therapeutics and Foghorn Therapeutics both had 5 articles in the media. Foghorn Therapeutics' average media sentiment score of 0.66 beat ImmuCell's score of 0.65 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmuCell	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Foghorn Therapeutics beats ImmuCell on 12 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Coeptis Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Coeptis Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 5.7% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ImmuCell has a net margin of -1.82% compared to Coeptis Therapeutics' net margin of -810.04%. ImmuCell's return on equity of -1.88% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
ImmuCell	-1.82%	-1.88%	-1.22%

ImmuCell has higher revenue and earnings than Coeptis Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	211.77	-$11.92M	-$2.52	N/A
ImmuCell	$27.64M	3.84	-$1.04M	-$0.06	N/A

In the previous week, ImmuCell had 4 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 5 mentions for ImmuCell and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.89 beat ImmuCell's score of 0.65 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coeptis Therapeutics	Very Positive
ImmuCell	Positive

Summary

ImmuCell beats Coeptis Therapeutics on 8 of the 13 factors compared between the two stocks.

Get ImmuCell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ICCC vs. The Competition

Export

Metric	ImmuCell	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$100.24M	$8.67B	$6.86B	$12.44B
Dividend Yield	N/A	2.55%	2.68%	8.42%
P/E Ratio	-195.30	15.65	26.94	24.38
Price / Sales	3.84	6.52	521.23	91.92
Price / Cash	57.47	18.09	48.59	59.36
Price / Book	3.92	3.56	10.89	6.33
Net Income	-$1.04M	$228.19M	$3.59B	$331.02M
7 Day Performance	10.25%	-1.41%	-1.53%	-0.33%
1 Month Performance	22.98%	-2.08%	2.72%	-1.29%
1 Year Performance	87.22%	2.26%	28.47%	21.30%

ImmuCell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ICCC ImmuCell	0.7776 of 5 stars	$11.72 +5.8%	N/A	+80.3%	$100.24M	$27.64M	N/A	70
AKBA Akebia Therapeutics	3.4547 of 5 stars	$1.42 +4.4%	$4.67 +228.6%	-64.7%	$380.93M	$232.40M	N/A	430	Short Interest Decrease
LRMR Larimar Therapeutics	4.3506 of 5 stars	$3.61 +5.9%	$12.71 +252.2%	+7.8%	$375.01M	N/A	N/A	30	Positive News
XFOR X4 Pharmaceuticals	2.9535 of 5 stars	$3.96 +0.5%	$9.38 +136.7%	+171.6%	$373.51M	$9.01M	N/A	80
FHTX Foghorn Therapeutics	2.7695 of 5 stars	$6.17 +2.8%	$11.43 +85.2%	-8.5%	$362.24M	$30.91M	N/A	120	News Coverage Analyst Downgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ICCC) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmuCell (ICCC) Competitors

ICCC vs. AKBA, LRMR, XFOR, FHTX, and ZSQR

How does ImmuCell compare to Akebia Therapeutics?

Summary

How does ImmuCell compare to Larimar Therapeutics?

Summary

How does ImmuCell compare to X4 Pharmaceuticals?

Summary

How does ImmuCell compare to Foghorn Therapeutics?

Summary

How does ImmuCell compare to Coeptis Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmuCell (ICCC) Competitors

ICCC vs. AKBA, LRMR, XFOR, FHTX, and ZSQR

How does ImmuCell compare to Akebia Therapeutics?

Do insiders and institutionals have more ownership in ICCC or AKBA?

Which has more risk and volatility, ICCC or AKBA?

Is ICCC or AKBA more profitable?

Does the media favor ICCC or AKBA?

Do analysts rate ICCC or AKBA?

Which has better valuation & earnings, ICCC or AKBA?

Summary

How does ImmuCell compare to Larimar Therapeutics?

Do insiders and institutionals believe in LRMR or ICCC?

Do analysts prefer LRMR or ICCC?

Which has better valuation and earnings, LRMR or ICCC?

Which has more volatility and risk, LRMR or ICCC?

Is LRMR or ICCC more profitable?

Does the media prefer LRMR or ICCC?

Summary

How does ImmuCell compare to X4 Pharmaceuticals?

Do analysts recommend ICCC or XFOR?

Which has more volatility & risk, ICCC or XFOR?

Does the media favor ICCC or XFOR?

Is ICCC or XFOR more profitable?

Which has better valuation and earnings, ICCC or XFOR?

Do insiders and institutionals hold more shares of ICCC or XFOR?

Summary

How does ImmuCell compare to Foghorn Therapeutics?

Which has better earnings & valuation, FHTX or ICCC?

Is FHTX or ICCC more profitable?

Do analysts prefer FHTX or ICCC?

Which has more risk & volatility, FHTX or ICCC?

Do insiders and institutionals have more ownership in FHTX or ICCC?

Does the media favor FHTX or ICCC?

Summary

How does ImmuCell compare to Coeptis Therapeutics?

Which has more volatility and risk, ZSQR or ICCC?

Do institutionals & insiders have more ownership in ZSQR or ICCC?

Do analysts rate ZSQR or ICCC?

Is ZSQR or ICCC more profitable?

Which has stronger earnings & valuation, ZSQR or ICCC?

Does the media favor ZSQR or ICCC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools